Overview

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether guanfacine represents a tolerable, potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving as compared to baseline.
Phase:
Phase 1
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Guanfacine